Victoria Navarro-Compán

Jan 11, 2025 | thelancet.com | Victoria Navarro-Compán |Alexandre Sepriano |Rheumazentrum Ruhrgebiet Herne

Get full text accessLog in, subscribe or purchase for full access. References1. Navarro-Compán, V ∙ Sepriano, A ∙ El-Zorkany, B ∙ et al. Axial spondyloarthritisAnn Rheum Dis. 2021; 80:1511-15212. Sieper, J ∙ Poddubnyy, DAxial spondyloarthritisLancet. 2017; 390:73-843. Garrido-Cumbrera, M ∙ Navarro-Compan, V ∙ Bundy, C ∙ et al. Axial Spondyloarthritis: patient-reported impact in Europe4. Kiltz, U ∙ Hoeper, K ∙ Hammel, L ∙ et al.

Jan 7, 2024 | nature.com | Victoria Navarro-Compán

Studies published in 2023 emphasize the long-term efficacy and safety of novel therapeutics for both radiographic and non-radiographic axial spondyloarthritis (axSpA) and provide a consensus definition of ‘early axSpA’ for use in research studies. Key advances In an open-label extension of the phase III SELECT-AXIS 2, upadacitinib demonstrated sustained efficacy in patients with radiographic axial spondyloarthritis (axSpA) refractory to treatment with biologic DMARDs2.